Trial ID or NCT#

NCT03745716

Status

RECRUITING

Purpose

A Phase III, multicenter, randomized study to compare the rate of complete response (CR) and duration of CR, in patients with TP53-mutated MDS who will receive APR-246 and azacitidine or azacitidine alone.

Official Title

A Phase III Multicenter, Randomized, Open Label Study of APR-246 in Combination With Azacitidine Versus Azacitidine Alone for the Treatment of (Tumor Protein) TP53 Mutant Myelodysplastic Syndromes

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Peter Greenberg
Hematologist, Medical oncologist, Leukemia specialist
Professor of Medicine (Hematology), Emeritus

Contact us to find out if this trial is right for you.

CONTACT

Anousheh Afjei
(650) 723-8594